1. Home
  2. ONTF vs NGNE Comparison

ONTF vs NGNE Comparison

Compare ONTF & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ON24 Inc.

ONTF

ON24 Inc.

N/A

Current Price

$8.03

Market Cap

341.1M

Sector

Technology

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$22.59

Market Cap

327.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ONTF
NGNE
Founded
1998
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
341.1M
327.8M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
ONTF
NGNE
Price
$8.03
$22.59
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$8.10
$60.13
AVG Volume (30 Days)
506.6K
157.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
12.93
N/A
EPS
N/A
N/A
Revenue
$148,081,000.00
$925,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.35
$6.88
52 Week High
$8.10
$37.27

Technical Indicators

Market Signals
Indicator
ONTF
NGNE
Relative Strength Index (RSI) 64.85 60.32
Support Level $7.84 $19.44
Resistance Level $8.09 $25.79
Average True Range (ATR) 0.04 2.29
MACD -0.02 0.35
Stochastic Oscillator 73.53 63.16

Price Performance

Historical Comparison
ONTF
NGNE

About ONTF ON24 Inc.

ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The Company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: